What You Should Know:
- Dexcom, announced today that the U.S. Food and Drug Administration (FDA) has cleared the Dexcom G7 15 Day Continuous Glucose Monitoring (CGM) System for individuals over the age of 18 with diabetes.
- The Dexcom G7 15 Day system boasts an overall Mean Absolute Relative Difference (MARD) of 8.0% and builds upon the proven performance of Dexcom CGM technology, which has been clinically demonstrated to lower A1C, reduce hyper- and hypoglycemia, and
Read More
Continuous Glucose Monitoring (CGM)
DME Providers Lead to Better CGM Adherence and Lower Healthcare Costs Compared to Pharmacies
What You Should Know:
- New research published in Clinical Diabetes, a peer-reviewed journal of the American Diabetes Association, reveals that patients receiving continuous glucose monitors (CGM) through durable medical equipment (DME) providers demonstrate significantly higher adherence and lower healthcare costs compared to those using pharmacy channels.
- The study, titled "Impact of Continuous Glucose Monitoring Sourcing on Real-World Adherence and Healthcare Costs: A
Read More
Glooko Integrates Abbott FreeStyle Libre CGM, Enhancing Diabetes Management
What You Should Know:
- Glooko, a provider of integrated digital health solutions for diabetes management, has announced a significant expansion of its platform's capabilities with the integration of Abbott’s FreeStyle Libre continuous glucose monitoring (CGM) systems in the United States.
- The newly implemented integration allows individuals with diabetes to seamlessly synchronize data from their FreeStyle Libre CGM systems with other vital health metrics, including insulin
Read More
Sequel Med Tech’s twiist AID System to Integrate Abbott’s FreeStyle Libre 3 Plus
What You Should Know:
- Sequel Med Tech, LLC, a company focused on developing cutting-edge insulin delivery technologies, has announced that its innovative twiist™ Automated Insulin Delivery (AID) System, powered by Tidepool, will be the first to integrate Abbott’s FreeStyle Libre 3 Plus sensor, a continuous glucose monitoring (CGM) device.
- The integration marks a pivotal moment for individuals with type 1 diabetes (T1D). The twiist AID System, expected to launch in Q2 2025, is
Read More
Senseonics and Ascensia Diabetes Care Integrate Eversense® 365 CGM with SweetSpot™ Platform
What You Should Know:
- Senseonics Holdings and Ascensia Diabetes Care today announced the integration of the Eversense® 365 Continuous Glucose Monitoring (CGM) System with the SweetSpot™ diabetes management platform in the U.S.
- The collaboration aims to improve patient care and streamline diabetes management for endocrinology practices and their patients.
Enhance Diabetes Management and Improve Patient Outcomes
The integration allows SweetSpot to seamlessly access and
Read More
Dexcom Introduces Generative AI Platform for Glucose Biosensing
What You Should Know:
- Dexcom, the global leader in continuous glucose monitoring (CGM), has achieved another groundbreaking milestone by launching the first generative AI (GenAI) platform in glucose biosensing technology, Stelo.
- The Stelo platform analyzes individual health data patterns to provide personalized insights and recommendations for improving metabolic health.
AI-Powered Personalized Guidance
The Dexcom GenAI platform leverages Google Cloud's Vertex AI and
Read More
Abbott’s FreeStyle Libre CGM Systems Now Cleared for Use During Imaging Procedures
What You Should Know:
- Abbott announced that its FreeStyle Libre 2 and 3 continuous glucose monitoring (CGM) systems have received FDA clearance for use during common imaging procedures, including X-rays, CT scans, and MRIs.
- The development makes Abbott's systems the first and only patient-applied CGM sensors approved for use during these screenings, offering greater convenience and potential cost savings for people with diabetes.
Improving Diabetes
Read More
Ascensia Launches World’s First One-Year CGM System, Eversense® 365
What You Should Know:
- Ascensia Diabetes Care has announced the U.S. launch of the Eversense® 365 continuous glucose monitoring (CGM) system, an advancement in diabetes management.
- Developed by Senseonics Holdings, Inc., Eversense 365 is the world's first and only CGM system to offer an entire year of continuous glucose monitoring with a single sensor. This innovative technology received FDA clearance last month for individuals with type 1 and type 2 diabetes aged 18 years
Read More
CGMs Through Medical Benefits: Improved Adherence and Cost Savings for Diabetes Patients, New Research Shows
What You Should Know:
- A research study by CCS, a leading chronic care management company, reveals that patients receiving continuous glucose monitoring (CGM) devices through medical benefits experience superior adherence and lower costs compared to those accessing them through pharmacy benefits.
- The JMIR Diabetes research — Exploring Real-World Adherence and Cost Implications of Continuous Glucose Monitoring in Patients with Diabetes: Impact of Device Sourcing, highlights
Read More
FDA Clears Eversense® 365: The World’s First One-Year CGM System
What You Should Know:
- Senseonics Holdings, Inc. and Ascensia Diabetes Care announced that the FDA has cleared the Eversense® 365 CGM system.
- This marks a significant advancement in diabetes management, offering a fully-implantable, long-term continuous glucose monitoring (CGM) solution for individuals with Type 1 and Type 2 diabetes aged 18 and older.
Eversense 365: Uninterrupted Living with Diabetes
Eversense 365 is set to transform the lives of people with diabetes by
Read More
